Vaccinex, Inc. (VCNX)
OTC PINK OTC PINK Primary Summary
Vaccinex, Inc. (VCNX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vaccinex, Inc. ever had a stock split?
Vaccinex, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Maurice Zauderer CEO | OTC PINK Exchange | 918640301 CUSIP |
| US Country | 25 Employees | - Last Dividend | 20 Feb 2024 Last Split | 9 Aug 2018 IPO Date |
Overview
Vaccinex, Inc. is a pioneering clinical-stage biotechnology company focused on the research and development of novel biotherapeutics for the treatment of various debilitating diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Founded in 2001 and based in Rochester, New York, the company is committed to leveraging its expertise in biology and proprietary technology platforms to create effective treatments that can significantly improve patients' lives. Its approach is characterized by a targeted strategy that aims to address the underlying causes of these complex diseases, thereby offering potentially transformative outcomes for patients.
Products and Services
- Pepinemab
This lead drug candidate epitomizes Vaccinex's innovative approach to biotechnology. Pepinemab is a humanized monoclonal antibody designed to bind and inhibit the activity of SEMA4D, a molecule implicated in the progression of various diseases. The drug is currently undergoing clinical trials in several critical areas:
- A Phase 1b/2 study for recurrent or metastatic head and neck cancer, where it aims to provide a new treatment avenue for patients with this challenging condition.
- A Phase 1/2a study in Alzheimer’s Disease to explore the potential of pepinemab in slowing or halting the progression of this devastating neurodegenerative disorder.
- Ongoing efforts to evaluate the feasibility of Phase 3 development for the treatment of Huntington's disease, offering hope for a new therapeutic option for this inherited condition.
- ActivMAb
A cutting-edge antibody drug discovery platform, ActivMAb represents another core component of Vaccinex's portfolio. This innovative platform is designed to tackle the most challenging targets in drug development, including multi-pass membrane receptors, and to facilitate the discovery of novel monoclonal antibodies. Utilizing a unique method that incorporates large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses, ActivMAb accelerates the identification and development of potential therapeutic antibodies for a wide range of diseases.
